![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: UIMC1 |
Gene summary for UIMC1 |
![]() |
Gene information | Species | Human | Gene symbol | UIMC1 | Gene ID | 51720 |
Gene name | ubiquitin interaction motif containing 1 | |
Gene Alias | RAP80 | |
Cytomap | 5q35.2 | |
Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | A0A024R7R0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51720 | UIMC1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.81e-05 | -4.14e-01 | 0.0155 |
51720 | UIMC1 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.19e-04 | -4.38e-01 | 0.096 |
51720 | UIMC1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.58e-07 | -3.05e-01 | 0.0674 |
51720 | UIMC1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.33e-04 | -3.34e-01 | 0.3005 |
51720 | UIMC1 | A015-C-203 | Human | Colorectum | FAP | 1.67e-22 | -3.95e-01 | -0.1294 |
51720 | UIMC1 | A015-C-204 | Human | Colorectum | FAP | 1.55e-05 | -3.64e-01 | -0.0228 |
51720 | UIMC1 | A014-C-040 | Human | Colorectum | FAP | 4.28e-03 | -5.10e-01 | -0.1184 |
51720 | UIMC1 | A002-C-201 | Human | Colorectum | FAP | 4.82e-12 | -4.21e-01 | 0.0324 |
51720 | UIMC1 | A002-C-203 | Human | Colorectum | FAP | 4.35e-04 | -2.32e-01 | 0.2786 |
51720 | UIMC1 | A001-C-108 | Human | Colorectum | FAP | 3.53e-11 | -3.48e-01 | -0.0272 |
51720 | UIMC1 | A002-C-205 | Human | Colorectum | FAP | 8.75e-14 | -3.22e-01 | -0.1236 |
51720 | UIMC1 | A015-C-005 | Human | Colorectum | FAP | 1.34e-02 | -2.39e-01 | -0.0336 |
51720 | UIMC1 | A015-C-006 | Human | Colorectum | FAP | 4.42e-09 | -3.25e-01 | -0.0994 |
51720 | UIMC1 | A015-C-106 | Human | Colorectum | FAP | 1.99e-09 | -2.51e-01 | -0.0511 |
51720 | UIMC1 | A002-C-114 | Human | Colorectum | FAP | 5.09e-12 | -3.91e-01 | -0.1561 |
51720 | UIMC1 | A015-C-104 | Human | Colorectum | FAP | 1.07e-21 | -3.67e-01 | -0.1899 |
51720 | UIMC1 | A001-C-014 | Human | Colorectum | FAP | 4.60e-10 | -2.82e-01 | 0.0135 |
51720 | UIMC1 | A002-C-016 | Human | Colorectum | FAP | 2.05e-21 | -4.26e-01 | 0.0521 |
51720 | UIMC1 | A015-C-002 | Human | Colorectum | FAP | 5.31e-07 | -3.61e-01 | -0.0763 |
51720 | UIMC1 | A001-C-203 | Human | Colorectum | FAP | 3.39e-09 | -3.07e-01 | -0.0481 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007064613 | Thyroid | ATC | protein modification by small protein removal | 71/6293 | 157/18723 | 1.59e-03 | 7.99e-03 | 71 |
GO:004573911 | Thyroid | ATC | positive regulation of DNA repair | 37/6293 | 73/18723 | 1.89e-03 | 9.24e-03 | 37 |
GO:004477313 | Thyroid | ATC | mitotic DNA damage checkpoint | 40/6293 | 81/18723 | 2.36e-03 | 1.10e-02 | 40 |
GO:007053611 | Thyroid | ATC | protein K63-linked deubiquitination | 20/6293 | 35/18723 | 3.56e-03 | 1.57e-02 | 20 |
GO:000007712 | Thyroid | ATC | DNA damage checkpoint | 53/6293 | 115/18723 | 3.59e-03 | 1.58e-02 | 53 |
GO:004477411 | Thyroid | ATC | mitotic DNA integrity checkpoint | 41/6293 | 85/18723 | 3.62e-03 | 1.58e-02 | 41 |
GO:190275011 | Thyroid | ATC | negative regulation of cell cycle G2/M phase transition | 31/6293 | 62/18723 | 5.52e-03 | 2.24e-02 | 31 |
GO:001097211 | Thyroid | ATC | negative regulation of G2/M transition of mitotic cell cycle | 30/6293 | 60/18723 | 6.27e-03 | 2.50e-02 | 30 |
GO:00315707 | Thyroid | ATC | DNA integrity checkpoint | 55/6293 | 123/18723 | 6.64e-03 | 2.65e-02 | 55 |
GO:00448182 | Thyroid | ATC | mitotic G2/M transition checkpoint | 24/6293 | 46/18723 | 7.13e-03 | 2.82e-02 | 24 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UIMC1 | SNV | Missense_Mutation | c.461N>G | p.Glu154Gly | p.E154G | Q96RL1 | protein_coding | tolerated(0.33) | benign(0.135) | TCGA-C8-A27A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
UIMC1 | SNV | Missense_Mutation | novel | c.1222N>C | p.Glu408Gln | p.E408Q | Q96RL1 | protein_coding | deleterious(0.01) | benign(0.224) | TCGA-S3-AA0Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Ancillary | neulasta | CR |
UIMC1 | SNV | Missense_Mutation | c.977N>G | p.Pro326Arg | p.P326R | Q96RL1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-FU-A3TQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
UIMC1 | insertion | Frame_Shift_Ins | novel | c.954_955insTCCTT | p.Gly319SerfsTer15 | p.G319Sfs*15 | Q96RL1 | protein_coding | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD | ||
UIMC1 | SNV | Missense_Mutation | c.350N>T | p.Ser117Ile | p.S117I | Q96RL1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
UIMC1 | SNV | Missense_Mutation | novel | c.1912N>A | p.Asp638Asn | p.D638N | Q96RL1 | protein_coding | tolerated(0.1) | possibly_damaging(0.846) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
UIMC1 | SNV | Missense_Mutation | novel | c.1054G>T | p.Asp352Tyr | p.D352Y | Q96RL1 | protein_coding | deleterious(0) | probably_damaging(0.935) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
UIMC1 | SNV | Missense_Mutation | rs779796802 | c.365N>A | p.Arg122Gln | p.R122Q | Q96RL1 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AG-A032-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | bevacizumab | PD |
UIMC1 | insertion | Nonsense_Mutation | novel | c.2034_2035insTACTAATGGTTTT | p.Val679TyrfsTer2 | p.V679Yfs*2 | Q96RL1 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
UIMC1 | SNV | Missense_Mutation | novel | c.1916N>A | p.Ala639Glu | p.A639E | Q96RL1 | protein_coding | deleterious(0) | benign(0.29) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |